BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PlainTrial//Saved Trials Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PlainTrial saved trials
X-WR-CALDESC:Estimated completion dates for the clinical trials you saved o
 n PlainTrial.
BEGIN:VEVENT
UID:plaintrial-NCT06989112-completion@plaintrial.com
DTSTAMP:20261027T161819Z
DTSTART;VALUE=DATE:20310219
SUMMARY:DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan 
 Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expres
 sing (IHC 3+/2+)\, Mismatch Repair Proficient (pMMR) Endometrial Cancer 
 — estimated completion date
DESCRIPTION:Recruiting. Saved on your PlainTrial shortlist. Full trial reco
 rd: https://plaintrial.com/trial/NCT06989112
URL:https://plaintrial.com/trial/NCT06989112
END:VEVENT
END:VCALENDAR